If you are 18 years old or older and have Type 1 diabetes, you may be interested in new research being conducted by the Faustman Lab at Massachusetts General Hospital.
The lab is currently recruiting participants for a Phase II human clinical trial of the Bacillus Calmette-Guérin (BCG) vaccine, an inexpensive generic tuberculosis drug, to determine the dose and schedule of the medicine needed to put advanced Type 1 diabetes into remission and prevent long-term diabetes complications. A Phase I study of the vaccine in adults who had been living with Type 1 diabetes for an average of 15 years demonstrated that the drug could help eliminate the defective immune system cells that mistakenly attack the insulin-producing cells in the pancreas and temporarily restore the ability of the pancreas to make insulin.
The lab is seeking adults age 18 and over who have had Type 1 diabetes for less than 20 years. There is no reimbursement for travel to Boston for the initial screening blood work, but those who are selected to participate in the trial will be compensated for the time and travel necessary for trial-related visits.
For more information, visit www.faustmanlab.org or contact the research team by e-mailing [email protected] or calling (617) 726-4084. And to learn more about the Faustman Lab, read this two-part interview with Dr. Denise Faustman.
This blog entry was written by Web Editor Diane Fennell.